Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios Ioannides

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of the American Academy of Dermatology|September 10, 2019
Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoringAimilios Lallas, Zoe Apalla, Athanassios Kyrgidis, et al.
Journal of the American Academy of Dermatology|November 30, 2020
Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safetyZoe Apalla, Ioannis Spyridis, Athanassios Kyrgidis, et al.
Journal of the American Academy of Dermatology|March 23, 2020
Dermoscopic predictors to discriminate between in situ and early invasive lentigo maligna melanoma: A retrospective observational studyLeonardo Peruilh-Bagolini, Zoe Apalla, Ruben González-Cuevas, et al.
Journal of the American Academy of Dermatology|August 9, 2020
Dermoscopic predictors of melanoma arising in small- and medium-sized congenital neviRuben González Cuevas, Alessia Villani, Zoe Apalla, et al.
Journal of the American Academy of Dermatology|February 19, 2020
Accuracy of dermoscopic criteria for the differential diagnosis between irritated seborrheic keratosis and squamous cell carcinomaChryssoula Papageorgiou, Ioannis Spyridis, Sofia Magdalini Manoli, et al.
Dermatology Practical & Conceptual|November 22, 2016
Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agentsAimilios Lallas, Giuseppe Argenziano, Iris Zalaudek, et al.
Dermatology and Therapy|April 2, 2026
Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENAMatthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, et al.
Dermatology and Therapy|May 15, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Jacek C Szepietowski, Lukasz Matusiak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 15, 2025
Management of folliculitis decalvans: The EADV task force on hair diseases position statementAnna Waśkiel-Burnat, Michela Starace, Matilde Iorizzo, et al.
Dermatologic Therapy|October 3, 2022
Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE studyDimitrios Rigopoulos, Charalampos Angelakopoulos, Zoi Apalla, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Dermatology|September 10, 2019
Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoringAimilios Lallas, Zoe Apalla, Athanassios Kyrgidis, et al.
Journal of the American Academy of Dermatology|November 30, 2020
Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safetyZoe Apalla, Ioannis Spyridis, Athanassios Kyrgidis, et al.
Journal of the American Academy of Dermatology|March 23, 2020
Dermoscopic predictors to discriminate between in situ and early invasive lentigo maligna melanoma: A retrospective observational studyLeonardo Peruilh-Bagolini, Zoe Apalla, Ruben González-Cuevas, et al.
Journal of the American Academy of Dermatology|August 9, 2020
Dermoscopic predictors of melanoma arising in small- and medium-sized congenital neviRuben González Cuevas, Alessia Villani, Zoe Apalla, et al.
Journal of the American Academy of Dermatology|February 19, 2020
Accuracy of dermoscopic criteria for the differential diagnosis between irritated seborrheic keratosis and squamous cell carcinomaChryssoula Papageorgiou, Ioannis Spyridis, Sofia Magdalini Manoli, et al.
Dermatology Practical & Conceptual|November 22, 2016
Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agentsAimilios Lallas, Giuseppe Argenziano, Iris Zalaudek, et al.
Dermatology and Therapy|April 2, 2026
Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENAMatthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, et al.
Dermatology and Therapy|May 15, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Jacek C Szepietowski, Lukasz Matusiak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 15, 2025
Management of folliculitis decalvans: The EADV task force on hair diseases position statementAnna Waśkiel-Burnat, Michela Starace, Matilde Iorizzo, et al.
Dermatologic Therapy|October 3, 2022
Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE studyDimitrios Rigopoulos, Charalampos Angelakopoulos, Zoi Apalla, et al.
Pageof 6